Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 5/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631185 | 0.80 | CYP1A2 (0.52) | CYP1A2CYP3A4ALDH1A1USP2CYP2D6 | |
| SCHEMBL4909469 | 0.79 | HTR7 (0.58) | HTR7HTR1AHTR6HTR2BHTR2A | |
| SCHEMBL2548096 | 0.77 | HTR7 (0.51) | CYP1A2CYP3A4ALDH1A1USP2CYP2D6 | |
| SCHEMBL8229622 | 0.77 | HTR7 (0.42) | CYP1A2CYP3A4ALDH1A1USP2CYP2D6 | |
| SCHEMBL6631182 | 0.75 | HDAC2 (0.48) | CYP1A2CYP3A4ALDH1A1USP2CYP2D6 | |
| SCHEMBL30009739 | 0.75 | HTR7 (0.66) | CYP1A2CYP3A4CYP2D6HSD17B10HTR7 | |
| SCHEMBL404317 | 0.75 | HTR7 (0.66) | CYP1A2CYP3A4CYP2D6HSD17B10HTR7 | |
| SCHEMBL4916238 | 0.74 | HTR7 (0.44) | ALDH1A1HTR7LMNAMAPTHTR1A | |
| SCHEMBL4915501 | 0.74 | HTR1A (0.47) | CYP1A2CYP3A4ALDH1A1USP2CYP2D6 | |
| SCHEMBL8226116 | 0.74 | KCNH2 (0.43) | HTR7HTR1AHTR6HTR2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | claimed |
| EP-1828156-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006065600-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| EP-1828156-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006065600-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | HTR2C, HTR2A, HTR5A | CYP1A2 33/4885CYP3A4 226/4885ALDH1A1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.